Navigating the commercialization of cell and gene therapies
This article was originally published on European Pharmaceutical Review (EPR) on May 19, 2025
Kevin Chinn, VP and Head of Cell and Gene Service Line at Cencora, talks about the hurdles to making cell and gene therapy a commercial success – and how to leap over them.
Read the article to explore the potential and major obstacles impacting cell and gene therapies in the pharmaceutical industry.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.